Table 3.
Characteristics of NMOSD patients with COVID-19 based on hospitalization status.
| Characteristics | Hospitalized | Non-hospitalized |
|---|---|---|
| Age, mean (SD) |
n = 37 46.54 (14.87) |
n = 55 37.36 (8.57) |
| Sex, female, n (%) |
n = 35 25 (71.4) |
n = 55 46 (83.6) |
| Disease duration, mean (SD) |
n = 34 9.35 (6.70) |
n = 55 7.57 (3.12) |
| EDSS, mean (SD) |
n = 21 4.50 (1.97) |
n = 47 2.94 (0.89) |
| AQP4-Ab, positive, n (%) |
n = 10 9 (90) |
n = 13 6 (46.1) |
| Comorbidity | n = 24 | n = 48 |
| At least one comorbidity, n (%) | 13 (54.2) | 23 (47.9) |
| Hypertension, n (%) | 6 (25.0) | 5 (10.4) |
| Heart diseases, n (%) | 2 (8.3) | 1 (2.1) |
| Diabetes mellitus, n (%) | 4 (16.7) | 3 (6.2) |
| Pulmonary disease, n (%) | 2 (8.3) | 3 (6.2) |
| Malignancy, n (%) | 1 (4.2) | 2 (4.2) |
| Autoimmune diseases, n (%) | 4 (16.7) | 5 (10.4) |
| Obesity, n (%) |
n = 25 9 (37.5) |
n = 55 11 (20.0) |
| Smoking, n (%) |
n = 25 1 (4.0) |
n = 55 3 (5.4) |
| Treatment | n = 37 | n = 55 |
| Rituximab, n (%) | 26 (70.3) | 22 (40.0) |
| Corticosteroid, n (%) | 4 (10.8) | 11(20.0) |
| Mycophenolate mofetil, n (%) | 4 (10.8) | 5 (9.1) |
| Azathioprine, n (%) | 6 (16.2) | 19 (34.5) |
| Ofatumumab, n (%) | 0 | 1 (1.8) |
| Inebilizumab, n (%) | 0 | 1 (1.8) |
| Eculizumab, n (%) | 0 | 1 (1.8) |
| Methotrexate, n (%) | 0 | 1 (1.8) |
| No treatment, n (%) | 1 (2.7) | 3 (5.4) |
n: number; SD: standard division; EDSS: expanded disability status scale; AQP4-Ab: aquaporin-4 antibody.